

Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20

By Mitchell E. Reff, Kristin Carner, Karen S. Chambers, Paul C. Chinn, John E. Leonard, Ron Raab, Roland A. Newman, Nabil Hanna, and Darrell R. Anderson

Murine monoclonal antibody 2B8 specifically recognizes the CD20 phosphoprotein expressed on the surface of normal B lymphocytes and B-cell lymphomas. The light- and heavy-chain variable regions of 2B8 were cloned, after amplification by the polymerase chain reaction, into a cDNA expression vector that contained human IgG1 heavy chain and human κ -light chain constant regions. High-level expression of chimeric-2B8 antibody (C2B8) was obtained in Chinese hamster ovary cells. Purified C2B8 exhibited antigen binding affinity and human-tissue reactivity similar to the native murine antibody. In vitro studies showed the ability of C2B8 to bind human C1q, mediate complement-dependent cell lysis of human B-lymphoid cell lines, and lyse human target cells through antibody-dependent cellu-

lar cytotoxicity. Infusion of macaque cynomolgus monkeys with doses ranging from 1.6 mg/kg to 6.4 mg/kg resulted in greater than 98% depletion of peripheral blood (PB) B cells and 40% to 70% depletion of lymph node B cells. Recovery of PB B cells usually started at 2 weeks after treatment and required 60 to greater than 90 days to reach normal levels. As much as 95% depletion of B cells in peripheral lymph nodes and bone marrow was observed following weekly injections of 16.8 mg/kg antibody. No toxicity was observed in any of the animals. These results offer the possibility of using an "immunologically active" chimeric anti-CD20 antibody as an alternative approach in the treatment of B-cell lymphoma.

© 1994 by The American Society of Hematology.

B LYMPHOCYTES ARISE from pluripotent stem cells and differentiate to fully mature antibody-secreting plasma cells.¹ The human B-lymphocyte-restricted differentiation antigen Bp35 (CD20), is a cell surface nonglycosylated hydrophobic phosphoprotein of 35 kD, and is expressed during early pre-B-cell development just before the expression of cytoplasmic μ -heavy chains.² Uncommitted hematopoietic-precursor stem cells do not express CD20. CD20 is expressed consistently until the plasma cell stage and regulates a step in the activation process that is required for cell-cycle initiation and differentiation.³⁻⁷

The CD20 molecule expressed on neoplastic B cells provides a promising target for therapy of B-cell lymphomas and leukemia.⁸ It is especially suitable as a target for antibody-mediated therapy because of accessibility and sensitivity of hematopoietic tumors to lysis by way of immune-effector mechanisms. The CD20 antigen is not normally shed from the cell surface, and there are no detectable serum levels of soluble CD20, which might block targeting of antibody to lymphomas.⁹ CD20 does not internalize after binding to antibody.¹⁰ Earlier studies have shown that partial clinical responses were achieved in lymphoma patients using high doses of murine anti-CD20 monoclonal (MoAb).⁸

We have identified a high-affinity murine anti-CD20 MoAb and constructed a mouse/human chimeric antibody that is expressed at high levels in mammalian cells. We have shown that the chimeric MoAb has specificity and affinity equivalent to the native-murine parent. However, unlike the murine antibody, the chimeric antibody binds human C1q, and mediates complement-dependent cell lysis (CDCC) in the presence of human complement, and antibody-dependent cellular cytotoxicity (ADCC) with human effector cells. Chimeric anti-CD20 antibody, when administered to cynomolgus monkeys, caused a marked B-cell depletion in peripheral blood (PB), bone marrow (BM), and lymphatic tissue.

MATERIALS AND METHODS

Production of murine anti-CD20 MoAb. Mice from the BALB/c strain were immunized weekly with the human lymphoblastoid cell line SB.¹¹ Splens were taken from mice with high serum titers of

anti-CD20 antibodies, and the splenocytes fused with the mouse myeloma SP2/0.¹² All assays for CD20 reactivity were accomplished by radio immunoassay. Briefly, purified anti-CD20 B1 (Coulter Corp, Hialeah, FL) was radiolabeled with ¹²⁵I by the iodobead method.¹³ Hybridomas were screened by coinubation with ¹²⁵I-B1 (10 ng) in 1% bovine serum albumin (BSA), phosphate-buffered saline (PBS), and 100,000 SB cells. After incubation for 1 hour at room temperature, the cells were harvested by transferring to 96-well filter plates (V&P Scientific, San Diego, CA) and washed thoroughly. Duplicate wells containing unlabeled B1 and wells containing no inhibiting antibody were used as positive and negative controls, respectively. Wells containing greater than 50% inhibitions were expanded and cloned. The antibody showing the highest reactivity was derived from the cloned cell line designated 2B8.

Construction of the chimeric anti-CD20 Ig DNA expression vector. RNA was isolated from the 2B8 mouse hybridoma cell¹⁴ from which single-stranded cDNA was prepared. Mouse Ig light-chain variable-region DNA was amplified from the cDNA by the polymerase chain reaction (PCR) using a set of DNA primers with homology to mouse light-chain signal sequences at the 5' end and mouse light-chain J region at the 3' end (see Fig 1 for primers). This DNA fragment was inserted directly into an expression plasmid in front of the human κ -light-chain constant domain and the entire construct sequenced. Two clones from two separate PCR reactions were sequenced to assure that no PCR errors occurred. The κ gene in the expression plasmid contained a synthetic signal sequence, unique restriction sites for the insertion of a light-chain variable domain, which maintain the reading frame and conserve the amino acids (Fig 2), and the human κ constant region (amino acid 108-214 Kabat numbering¹⁵). A schematic drawing of the expression plasmid can be found in Fig 3. The mouse light-chain variable region from 2B8 is in the mouse κ VI family.¹⁵ Similarly, the mouse

From IDEC Pharmaceuticals Corp, San Diego, CA.

Submitted April 5, 1993; accepted September 21, 1993.

Address reprint requests to Darrell R. Anderson, PhD, IDEC Pharmaceuticals Corporation, 11011 Torreyana Rd, San Diego, CA 92121.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1994 by The American Society of Hematology.

0006-4971/94/8302-0021\$3.00/0

KAPPA INSERT SITE

LEADER

-20

AGA TCT CTC ACC ATG AGG GTC CCC GCT CAG CTC CTG
 MET ARG VAL PRO ALA GLN LEU LEU
Bgl I I **Ppu MI**

-10

GGG CTC CTG CTG CTC TGG CTC CCA GGT GCA CGA TGT GAT
 GLY LEU LEU LEU LEU TRP LEU PRO GLY ALA ARG CYS ASP
Dra III

101 107
 GGT ACC AAG GTG GAA ATC AAA
 GLY THR LYS VAL GLU ILE LYS
Kpn I

J REGION

108 109
CGT ACG
 ARG THR
Bsi WI

HUMAN KAPPA CONSTANT

GAMMA 1 INSERT SITE

LEADER

-19 -10

GTC GAC ATG GGT TGG AGC CTC ATC TTG CTC TTC CTT
 MET GLY TRP SER LEU ILE LEU LEU PHE LEU
Sal I

-5 -4 -3

GTC GCT GTT GCT ACG CGT GTC
 VAL ALA VAL ALA THR ARG VAL
Mlu I

114 115
GCT ACG
 ALA SER
Nhe I

HUMAN GAMMA 1 CONSTANT

Fig 2. DNA sequence of the Ig vector indicating restriction endonuclease sites where variable-region DNA can be cloned. The PCR-DNA fragments of anti-CD20 were cloned into the *Bgl* I and *Bsi* WI (Kappa) and *Mlu* I and *Nhe* I (Gamma 1) sites, respectively.

added to two of the tubes for identifying T- and B-lymphocyte populations. C2B8 antibody bound to monkey B-cell surface CD20 was measured in the third tube using polyclonal goat-antihuman IgG coupled with phycoerythrin (AMAC). This reagent was preabsorbed on a monkey IgG-Sepharose column to eliminate background staining of monkey surface-IgG⁺ B cells. A fourth sample was included for autofluorescence. Cells were incubated with antibodies for 30 minutes, washed and fixed with 0.5 mL of fixation buffer (0.15 mol/L NaCl, 1% paraformaldehyde), and analyzed on a Becton Dickinson FACScan instrument. Fluorescence measurements reflected only gated lymphocyte events.

Depletion of B cells from primate PB. Four cynomolgus monkeys ranging in weight from 4.5 to 7 kg received doses of C2B8 corresponding to 0.01 mg/kg, 0.1 mg/kg, 0.4 mg/kg, and 1.6 mg/kg each day for 4 consecutive days. Therefore, the dose range was 0.04 to 6.4 mg/kg body weight. The antibody was administered by intravenous infusion with blood samples drawn before each infusion. Additional blood samples beginning 24 hours after the last injection were taken at days 1, 2, 4, 8, 15, 29, and subsequently thereafter at biweekly intervals until completion of the study at day 90. Approx-

imately 5 mL of whole blood from each animal was centrifuged at 2,000 rpm for 5 minutes. The pellet containing PB leukocytes and red blood cells was resuspended in fetal calf serum for staining with fluorescent antibodies.

Depletion of B cells from primate lymph nodes. Four cynomolgus monkeys ranging in weight from 4 to 6 kg were divided into two groups of two monkeys. One group was injected intravenously with a dose of 1.6 mg/kg (0.4 mg/kg each day for 4 consecutive days). The animals in the other group were injected with a single dose of 6.4 mg/kg. Animals were bled after the last injection at days 1, 2, 4, 8, 15 and 22, and blood was processed the same as before for fluorescent antibody staining. Lymph node biopsies from the inguinal area of the leg were taken at days 15 and 29 with cell preparations stained for quantitation of lymphocyte populations by flow cytometry. A lymph node biopsy was also taken from a normal animal injected with saline. The percent of B lymphocytes in the total lymphocyte fraction, detected by flow cytometry in the normal animal, was used as a reference for comparing the percentage of B lymphocytes in the lymph nodes of the treated animals. Depletion of lymph nodes was quantitated by assuming the fraction of B lymphocytes in normal saline-treated animals to be approximately 40%. Reduced amounts of B cells found in treated lymph nodes were calculated as percent depleted B cells by the following formula:

$$\% \text{ Depletion} = 100 - \frac{\% \text{ B Cells in Treated Lymph Node}}{\% \text{ B Cells in Saline Control}}$$

High-dose in vivo pharmacology study. Four monkeys were infused with 16.8 mg/kg C2B8 at weekly intervals over a period of 4 consecutive weeks. At 22 days beyond the end of the dosing period, two animals were anesthetized for removal of BM and lymph node biopsies. At 36 days beyond the end of the dosing period, the two remaining animals were anesthetized for BM and lymph node biopsies. Both sets of tissues were stained for the presence of B lymphocytes using the CD20 marker Leu-16 by flow cytometry.¹⁹

Evaluation of animal systemic and tissue toxicity. All animals used in the in vivo studies were routinely examined for toxic side effects during the course of the studies by routine blood chemistry, urinalysis, and physical examination including weight loss and loss of appetite. Two of the four animals in the multiple high-dose study were killed at the end of the study at 22 days after final dosing. Body tissues were thoroughly examined for evidences of toxicity and tissue damage.

RESULTS

Construction and expression of chimeric 2B8 antibody. The light and heavy chain variable regions from the murine 2B8 anti-CD20 antibody were cloned using PCR amplification and inserted directly into a cDNA mammalian chimeric antibody expression vector. The expression vector (TCAE see Fig 3) contains four separate eukaryotic cDNA genes arranged in a tandem head to tail fashion, each containing its own promoter and polyadenylation region. The four genes are the human κ gene (allotype Km3),¹⁵ the human γ -1 constant gene (allotype z, a),¹⁵ a neomycin phosphotransferase gene (NEO),²⁰ and a mouse dihydrofolate reductase (DHFR) gene.²¹ The NEO gene is used for selecting mammalian cell clones that have integrated the gene and are resistant to the antibiotic G418.¹⁹ The DHFR gene is used for gene amplification in the presence of the competitive substrate inhibitor methotrexate.²²




Fig 3. Schematic representation of the DNA expression vector tandem chimeric-antibody expression used to express anti-CD20 in CHO cells. L, leader; CMV, cytomegalovirus promoter; BETA, mouse β -globin major promoter; BGH, bovine growth hormone polyadenylation; SV, SV40 early polyadenylation; SV ORI, SV40 origin.

After electroporation into CHO cells and selection in G418, drug-resistant clones were isolated from cells that secreted $2 \mu\text{g}/10^6$ cells/d. Cell lines have been derived in 5 nmol/L methotrexate in a single amplification step that secrete stable Ig levels at $30 \mu\text{g}/10^6$ cells/d.

Antibody specificity and immunoreactivity. Chimeric anti-CD20 was purified by protein-A affinity chromatography and estimated to be greater than 95% pure by electrophoresis on polyacrylamide gels. It was first tested in direct and competitive binding assays and compared with murine 2B8, where it was shown to be of comparable affinity and specificity on CD20⁺ SB cell line. The apparent-affinity constant (K_{ap}) was determined by direct binding of radiolabeled C2B8 and compared with radiolabeled murine 2B8 by Scatchard analysis. The K_{ap} of C2B8 was estimated as 5.2×10^{-9} mol/L (Fig 4), compared with a K_{ap} of approximately 3.5×10^{-9} mol/L for the murine antibody. Direct competition by radioimmunoassay was used to confirm both the specificity and retention of immunoreactivity of the chimeric antibody by comparing its ability to effectively compete with binding of native murine antibody. Data illustrated in Fig 5 shows that virtually equivalent amounts of chimeric and native murine antibody were required to inhibit the binding of the parent murine-2B8 antibody to CD20 sites on SB cells.

In vitro functional characterization of C2B8 antibody. C2B8 was evaluated for human C1q binding by flow cytometry, as shown in Fig 6. In this assay, when C2B8 was incu-

bated with SB cells followed by the addition of fluorescein-labeled C1q, a significant increase in fluorescent intensity was observed. In contrast, under the same conditions, murine-2B8 antibody, as well as an irrelevant human IgG1 (data not shown), failed to bind human C1q.

C2B8 was then tested for its ability to lyse B-lymphoid cell lines in the presence of human serum as a source of complement. Approximately 50% of the SB target cells (Fig 7) were lysed in the presence of a $2.2 \mu\text{g}$ concentration of C2B8 antibody and a 1:4 dilution of human complement (Pel Freeze, Rogers, AK). In contrast, no significant lysis was observed in experiments using CD20⁺ SB cells incubated with murine-2B8 antibody, or CD20⁻ HSB cells incubated with C2B8 antibody. A summary of data from an ADCC assay using C2B8 and activated human effector cells at a 100:1 effector:target ratio is presented in Fig 8. Approximately 50% of the antigen⁺ SB cells were lysed during the 4-hour incubation period. In contrast, CD20⁻ HSB cells were not lysed nor were CD20⁺ cells incubated with murine-2B8 antibody.

In vivo depletion of PB B lymphocytes. Cynomolgus monkeys received doses of C2B8 corresponding to 0.01, 0.1, 0.4, and 1.6 mg/kg daily for a total of 4 consecutive days resulting in total doses ranging from 0.04 to 6.4 mg/kg. The data in Fig 9 shows that doses of 0.4 to 6.4 mg/kg depleted greater than 95% of PB B cells for as long as 8 days postinfusion. The lowest dose (0.04 mg/kg) effectively depleted greater than 50% of the peripheral B cells. It is also apparent




Fig 4. Determination of K_{ap} for chimeric antibodies produced in CHO transfectoma. Antibodies produced in the CHO cell and the original murine cell line were purified, radiolabeled with ^{125}I , and evaluated by direct binding to CD20 antigen expressed on 10,000 human SB cells. Apparent binding affinities were determined by Scatchard plots. (●) 2B8; (□) C2B8.

from the CD20 marker, Leu-16, that saturation of the CD20 antigen on the B-lymphocyte population in PB was not achieved with this dose of C2B8 antibody (Table 1). Table 1 compares the percentage of cells coated with C2B8 and the




Fig 5. Immunoreactivity of purified antibodies produced by CHO transfectoma. Unlabeled chimeric 2B8 was incubated at various concentrations in the presence of 10,000 B-lymphoid cells and 10 ng of ^{125}I -labeled native-murine 2B8. The amounts of chimeric antibody required to directly compete with the radiolabeled murine anti-CD20 antibody were compared with similar amounts of unlabeled murine antibody. Results indicate minimal loss of inhibiting activity due to chimerization. (●) 2B8; (□) C2B8.

percentage of CD20⁺ cells. The percentage of C2B8-coated cells at the lowest dose is basically identical to the CD20⁺ cells at 24 hours. By day 2, the percent of C2B8-coated cells is only half that of the population of CD20⁺ cells. Total saturation at 24 hours would have blocked binding of Leu-16 to these cells, as both reagents compete with each other for the same site on SB cells. At 0.04 and 0.4 mg/kg dose levels, B lymphocytes coated with C2B8 antibody were detected in the circulation during the initial 4 days after antibody infusion. By day 8, C2B8 antibody-coated cells at all doses were undetectable in PB. The levels of C2B8-coated cells were very low at the higher doses, presumably because of the absence of B cells by 24 hours. After day 8, the B cells began





Fig 6. Binding of fluorescent-C1q to Chimeric MoAb C2B8 associated with antigen on the surface of human B-lymphoid cells detected by flow cytometry. Purified-C2B8 and murine-2B8 antibodies were incubated with human SB cells, washed to remove unattached antibody and incubated with fluoresceinated C1q. Cells were washed again, fixed and C1q fluorescence measured by flow cytometry. Controls were C1q-FITC and C1q-FITC plus irrelevant human IgG1, κ .




Fig 7. Chimeric C2B8 (■) was compared with murine 2B8 (□) for complement-related lysis in a concentration of 2.2 μ g/mL. Ten thousand SB cells (CD20⁺) were labeled with Cr⁵¹ followed by incubation in the presence of anti-CD20 antibodies and human complement was used at a 1:4 dilution (Pel Freeze). CD20⁻ control cell line was 10,000 HSB cells.




Fig 8. ADCC with *in vitro* human effector cells comparing chimeric-C2B8 and murine-2B8 lysis of human lymphoid target cells. C2B8 (■) and 2B8 (□) concentration with target cells was 3.9 μ g/mL. Human peripheral lymphocytes were used as effector cells in a 100:1 ratio to target cells previously loaded with Cr⁵¹. CD20⁻ control cells were HSB at the same effector to target ratio.




Fig 9. Depletion of PB B lymphocytes in cynomolgus primates infused with four daily injections of C2B8 antibody purified from CHO transfectoma. Fluorescein-labeled MoAb with specificity for human B lymphocytes (Leu-16, anti-CD20; Becton Dickinson) was used to stain and detect the B-lymphocyte population. Dose: (■) 0.04 mg/kg; (●) 0.4 mg/kg; (△) 1.6 mg/kg; (□) 6.4 mg/kg.

a slow recovery. This occurred more rapidly in some monkeys than others and was seemingly dose independent.

In vivo depletion of B lymphocytes in peripheral lymph nodes. The objective of this study was to determine the effects of the two highest C2B8 doses that previously depleted greater than 98% of the B cells in the PB on the lymph node B-cell populations. The results summarized in Table 2 are obtained from lymph node biopsies of four animals infused with 1.6 mg/kg or 6.4 mg/kg of C2B8 and a single control animal injected with saline. Examination of lymphatic tissue removed on days 15 and 29 after administration of 1.6 and 6.4 mg/kg shows effective depletion of B lymphocytes (Table 2). B-cell depletion varied widely in individuals from both dose groups ranging from 34% to 78%, based on calculations using 39.5% B cells present in the inguinal node of a saline-treated animal. In the most highly depleted individuals, a major increase in the percentage of T cells was observed, confirming the depletion of B cells. In each of the antibody doses used (Table 2), complete depletion of the B cells in the lymphatic tissue with C2B8 still was not achieved, day 15 and day 29 B-cell populations were quite similar in each animal indicating most of the depletion occurred before day 15, with very little regeneration within the first 30 days.

Using the data derived from these studies, a high-dose pharmacology/toxicology study of C2B8 in cynomolgus monkeys was conducted. This protocol was designed to evaluate the toxicity (if any) associated with the administration of C2B8, as well as the efficacy of B-cell depletion from lymph nodes and BM. Also, because the majority of lymph node B cells were depleted within 15 days after antibody

Table 1. Coating of CD20 Antigen Positive B Lymphocytes in PB of Cynomolgus Monkeys Treated With Various Doses of C2B8 Antibody

Monkey	Dose (mg/kg)	Day	Percent of Total Lymphocytes		
			Leu-16 ⁺ B Cells*	C2B8 ⁺ Cells†	CD2 ⁺ T Cell‡
672	0.04	Pre	16.7	0	74.7
		1	11.7	11	74.7
		2	13.0	6.3	80.6
		4	8.5	2.6	80.6
		8	7.4	0.2	82.7
848	0.4	Pre	12.4	0	80.1
		1	0.1	1.3	85.7
		2	0.1	0.7	87.8
		4	0.1	0.6	90.7
		8	1.6	0.5	88.5
660	1.6	Pre	28.3	0	72.9
		1	0.4	0.4	94.0
		2	0.1	0.2	95.6
		4	0.1	0.4	96.2
		8	0.0	0.3	96.0
427	6.4	Pre	7.1	0	84.7
		1	0.0	0.1	92.1
		2	0.0	0.2	92.0
		4	0.0	0.2	94.1
		8	0.0	0.1	91.3

* Determined as a percentage of the total gated lymphocyte population by flow cytometry using the CD20 marker antibody, Leu-16-FITC.

† Determined as a percentage of the total gated lymphocyte population by detecting the percentage of C2B8-coated cells using monkey IgG absorbed goat antihuman-phycoerythrin (RPE).

‡ Determined as a percentage of the total gated lymphocytes using the CD2 specific antibody T-cell marker (antihuman CD2-RPE, AMAC).

treatment, a weekly dosing regimen was adopted. In this study, four animals were given four weekly doses of approximately 16.8 mg/kg C2B8. At the completion of the dosing schedule, lymph node and BM specimens were removed and analyzed by flow cytometry for the presence of CD20⁺ B cells. Two animals were examined at 22 days after the last dose and the other two examined at 36 days. Figure 10 illustrates the results of a typical flow cytometry experiment with one of the monkeys used in the study. Two normal animals treated with saline were examined for comparable lymph node and BM tissues. Figure 11 histograms compare T-cell populations in normal animals and depleted animals from both lymph node and BM tissue specimens. Table 3 summarizes the results of all the animals in the study. It can be seen that lymph nodes from both animals evaluated at 22 days after cessation of treatment contained from 5.3% to 6.3% B cells as compared with 39.5% in control lymph nodes (Table 3). Similarly, in the BM of these animals, the levels of CD20⁺ cells ranged from 3% to 4.3%, as compared with 16.6% in the normal animal. In animals evaluated at 36 days after cessation of treatment, studies showed that one of two animals had approximately 12% B cells in the lymph node and 4.4% B cells in BM. The other animal had approximately 5% and 0.8% B cells in the lymph node and BM, respectively. T-cell populations generally increased dramati-

cally with the absence of B cells in lymph nodes, ranging from 85% to 90%. T-cell populations in the BM of depleted animals ranged from slightly below normal at 25.6% to slightly over 46%. The normal control animal 908 BM sample had 29.8% T cells.

All animals used in the in vivo studies were routinely examined for symptoms of toxicity during the course of the studies by routine blood chemistry, urinalysis, and physical examination. Two of the four animals in the multiple high-dose study were killed at the end of the study at 22 days after final dosing. Body tissues were thoroughly examined for evidences of toxicity and tissue damage. No weight loss or other visible effects of antibody treatment other than loss of B cells were noted.

DISCUSSION

MoAbs have been used for therapy of hematologic malignancies. Radiolabeled, toxin-conjugated, and unmodified MoAbs have all been tested clinically.^{8,23-25} Some of the problems associated with MoAb therapy of neoplasms include specificity of the antibody for tumor cells as opposed to normal tissues, heterogeneity of tumor-specific antigen expression, low distribution of antibody in solid neoplasms, human antimouse antibody responses, which often limit the usefulness of murine antibodies for repeated therapy, and toxicity of radiolabeled or toxin-conjugated antibodies.²³

We have expressed at high levels a chimeric mouse/human MoAb to CD20, a cell-surface phosphoprotein expressed on cells of the B-cell lineage. We have shown that the chimeric antibody, C2B8, has specificity and affinity equivalent to the mouse MoAb from which it was derived. The chimeric antibody has shown human effector functions using in vitro assays for C1q binding, complement-mediated cell lysis and antibody-dependent cellular-mediated cytotoxicity. Unlike its mouse counterpart (data not shown),

Table 2. T- and B-Lymphocyte Populations in Lymph Node Biopsies Taken From C2B8-Treated Cynomolgus Monkeys, 15 and 29 Days After Treatment

Monkey	Dose (mg/kg)	Day	% CD2 ⁺ *	% CD20 ⁺ †	% Depletion‡
425	Saline	ND	ND	ND	0
684	1.6	15	76.9	22.6	42.8
688	1.6	15	83.2	14.5	63.3
692	6.4	15	74.1	23.9	39.5
696	6.4	15	74.1	8.7	77.9
425	Saline	29	52.1	39.5	0
684	1.6	29	61.6	26.0	34.2
688	1.6	29	84.1	14.6	63.0
692	6.4	29	66.9	21.4	45.8
696	6.4	29	84.1	12.9	67.3

Abbreviation: ND, not determined.

* Determined by flow cytometry with antihuman CD2-RPE (AMAC).

† Determined by flow cytometry with Leu-16 antihuman CD20-FITC (Becton Dickinson).

‡ Values calculated assuming 39.5% B cells from a normal animal treated with saline and biopsied at day 29 after last saline injection. Day 15 and day 29 treated animals all calculated based on 39.5% B cells in normal lymph node.

B Cell Population




Fig 10. Depletion of monkey lymph node and BM B lymphocytes after infusion of four weekly 16.8 mg/kg doses of C2B8. Chimeric C2B8 was injected into four monkeys: 677, 892, 681, and 884. Inguinal lymph nodes were surgically removed for flow cytometry cell analysis along with BM aspirates. Monkey-681 B-lymphocyte BM and lymph node histograms compared with nondepleted animals 425 (lymph node) and 908 (BM), injected with saline. C2B8-treated monkey 681 was examined at 36 days after last injection.

a low dose of chimeric anti-CD20 leads to long-term peripheral B-cell depletion in primates. Furthermore, significant depletion of B-cell populations was achieved in peripheral lymph nodes and BM when repetitive high doses were administered.

We have chosen CHO transfectomas to produce antibody for future clinical trials because of the previous use in humans of other CHO-derived recombinant proteins, and because we are able to derive CHO cells that secrete 80 to 100 $\mu\text{g}/10^6$ cells/d. These transfectomas are capable of producing greater than 1 g/L in short fermentation-tank studies.

C2B8 antibody has shown *in vivo* characteristics that support its use in treatment of B-cell malignancies. Tumors of this type are particularly accessible and readily susceptible to immunotherapy.²⁶ The CD20 target is strongly expressed on most B-lymphocyte tumors and is not shed into the circulation nor expressed in nonhematopoietic tissues, where it could interfere with antibody therapy. The concern for immunoreactivity against mouse/human chimeric antibodies is reduced because of the immunocompromised nature of lymphoma patients^{27,28} and perhaps aided further by the human constant region.²⁹ We have not yet compared di-

T Cell Population




Fig 11. T-cell populations in monkey lymph node and BM tissues after infusion of four weekly 16.8 mg/kg doses of C2B8. Chimeric C2B8 was injected into four monkeys: 677, 681, 884, and 892. Inguinal lymph nodes were surgically removed from anesthetized animals for immunohistochemical staining and flow cytometry cell analysis along with BM aspirates. Monkey-681 T-lymphocyte BM and lymph node histograms compared with nondepleted animals 425 (lymph node) and 908 (BM), injected with saline. C2B8-treated monkey 681 was examined at 36 days after last injection.

rectly in monkeys the immunogenicity of the murine and chimeric antibodies. We have analyzed all antibodies produced in these animals against C2B8 and found them to be exclusively anti-idiotypic and antijoining region specific. None of these antibodies cross-react to other human or murine antibodies; however, immunogenicity still remains an issue for further investigation.

Despite the fact that all animals were dramatically de-

pleted of peripheral B lymphocytes during the first week after treatment, there have been no adverse effects observed in any of the treated animals. In our studies, all antibody-treated monkeys have shown no apparent depletion of other cell types; however, the lack of suitable marker reagents for monkey hematopoietic tissues other than B- or T-lymphocytes, have made it difficult to establish this claim with certainty. Lymph nodes in B-cell-depleted animals become al-

Table 3. T- and B-Lymphocyte Populations in Lymph Node and BM Biopsies Taken From Cynomolgus Monkeys Treated with Four Weekly Doses (16.8 mg/kg) of C2B8

Monkey	% CD2* [†]	% CD20* [†]	Day [‡]	Dose (mg/kg)	% Depletion [§]
Inguinal lymph node					
425	52.1	39.5	29	Saline	0
677	90	5.3	22	16.8	86.6
892	91	6.3	22	16.8	84.1
681	89.9	5.0	36	16.8	87.4
884	85.4	12.3	36	16.8	68.9
Bone marrow					
677	46.7	4.3	22	16.8	74.1
892	41.8	3.0	22	16.8	81.9
681	35.3	0.8	36	16.8	95.2
884	25.6	4.4	36	16.8	73.5
908	29.8	16.6	36	Saline	0

* Determined by flow cytometry with antihuman CD2-RPE (AMAC). Values are percentages of total lymphocytes.

† Determined by flow cytometry with Leu-16 antihuman CD20-FITC (Becton Dickinson). Values are percentages of total lymphocytes.

‡ Days after final weekly injection.

§ Values are calculated assuming 39.5% of total lymphocytes in animal 425 treated with saline as B-cell fraction in a normal lymph node. Percent depletion represents the decreased fraction of B cells compared with the normal lymph node, found in the treated animals. The percent depletion of BM calculated in treated animals was based on fraction of B cells in normal BM sample from saline animal 908 as 16.6% B cells.

most entirely populated with T cells. All nonsacrificed animals in the studies eventually recovered their B-cell populations, indicating that monkey pluripotent stem cells are not affected. This is further supported by our *in vitro* studies on human BM stem cells (data not shown), which demonstrated that the CD20 antigen is not expressed on stem cells. In addition, other studies in humans that have used anti-CD20 antibodies to purge BM have seen no adverse effects on BM reconstitution.³⁰

The application of C2B8 to human lymphoma therapy will provide a much greater challenge than the primate model described here. Human disease will likely present excessive tumor burdens within lymphatic tissues involving bulky fibroidal lesions with markedly decreased accessibility.²³ Our present plans are to determine how effective C2B8 is in reducing tumor bulk or in eradicating micrometastases in patients suffering from non-Hodgkin's B-cell lymphoma.

ACKNOWLEDGMENT

The authors thank Mabel Hernandez and Nora Morris for preparing the manuscript, and Robert McCoobery and James Alberts for excellent technical assistance. We are grateful to Ken Woolcott and Dr William Rastetter for providing useful critical comments to the manuscript.

REFERENCES

1. Calvert JE, Maruyama S, Tedder TF, Webb CF, Cooper MD: Cellular events in the differentiation of antibody secreting cells. *Semin Hematol* 21:226, 1984

2. Valentine MA, Meier KE, Rossie S, Clark EA: Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. *J Biol Chem* 264:11282, 1989

3. Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhaupt B, Park E, Jansen J, Coral F, Mayer RJ, Dalla SE, Ritz J, Schlossman SF: B cell origin of non-T cell acute lymphoblastic leukemia. *J Clin Invest* 74:332, 1984

4. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. *J Immunol* 135:973, 1985

5. Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF: Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. *Eur J Immunol* 16:881, 1986

6. Golay JT, Clark EA, Beverley PCL: The CD20 (Bp35) antigen is involved in activation of B cells from the G₀ to the G₁ phase of the cell cycle. *J Immunol* 135:3795, 1985

7. Clark EA, Shu G, Ledbetter JA: Role of the Bp35 cell surface polypeptide in human B-cell activation. *Proc Natl Acad Sci USA* 82:1766, 1985

8. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. *Blood* 69:584, 1987

9. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. *EMBO J* 7:711, 1988

10. Liu AY, Robinson R Jr, Murray ED, Ledbetter JA, Hellström I, Hellström KE: Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. *J Immunol* 139:3521, 1987

11. Adams RA, Flowers A, Davis BJ: Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2. *Cancer Res* 28:1121, 1968

12. Shulman M, Wilde CD, Kohler G: A better cell line for making hybridomas secreting specific antibodies. *Nature* 276:269, 1978

13. Markwell MAK: A new solid-state reagent to iodinate proteins I. conditions for the efficient labeling of anti-serum. *Anal Biochem* 125:427, 1982

14. Chomczynski P, Nicoletta S: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156, 1987

15. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C: Sequences of Proteins of Immunological Interest (ed 5). NIH Publication No. 91-3242. Bethesda, MD, National Institutes of Health, 1991

16. Urlaub G, Mitchell PJ, Kas E, Chasin LA, Funanage VL, Myoda T, Hamlin J: Effect of gamma rays at the dihydrofolate reductase locus: Deletions and inversions. *Somat Cell Mol Genet* 16:555, 1986

17. Adams RA: Formal discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma. *Cancer Res* 27:2479, 1967

18. Brunner KT, Mauel J, Cerottini JC, Chapuis B: Quantitative assay of the lytic action of immune lymphoid cells on ⁵¹Cr-labelled allogeneic target cells *in vitro*: inhibition by isoantibody and by drugs. *Immunology* 14:181, 1968

19. Ling NR, MacLennan ICM, Mason DY: B-cell and plasma cell antigens: New and previously defined clusters, in McMichael AJ (ed): Leucocyte Typing III: White Cell Differentiation Antigens. Oxford, UK, Oxford University, 1987, p 302

20. Colbere-Garapin F, Horodniceanu F, Kourilsky P, Garaphin AC: A new dominant hybrid selective marker for higher eukaryotic cells. *J Mol Biol* 150:1, 1981

21. Subramani S, Mulligan R, Berg P: Expression of the mouse dihydrofolate reductase complementary deoxyribonucleic acid in simian virus 40 vectors. *Mol Cell Biol* 9:854, 1981
22. Kaufman R, Sharp PA: Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene. *J Mol Biol* 159:601, 1982
23. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. *Blood* 80:863, 1992
24. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blattler WA, Taylor JA, Nadler LM: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. *Blood* 79:576, 1992
25. Press OW, Eary JF, Badger CC, Appelbaum F, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes K, Porter B, Kidd P, Thomas ED, Bernstein ID: Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. *J Clin Oncol* 7:1027, 1989
26. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. *Cancer Res* 40:3147, 1980
27. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R: A clinical trial of anti-idiotypic therapy for B-cell malignancy. *Blood* 65:1349, 1985
28. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R: Treatment of B-cell lymphomas with anti-idiotypic antibodies alone and in combination with alpha interferon. *Blood* 73:651, 1989
29. Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann W: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody campath-1H. *Lancet* 332:1394, 1988
30. Anderson KC, Ritz J, Takvorian T, Coral F, Daley H, Gorgone BC, Freedman AS, Canellos GP, Schlossman SF, Nadler LM: Hematologic engraftment and immune reconstitution post-transplantation with anti-B1 purged autologous bone marrow. *Blood* 69:597, 1987